Onco-Innovations Limited
ONCO
CNSX
| 10/31/2024 | 07/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 110.30K | 99.90K | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 132.30K | 118.20K | |||
| Operating Income | -132.30K | -118.20K | |||
| Income Before Tax | -132.60K | -231.40K | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -132.60K | -231.40K | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -132.60K | -231.40K | |||
| EBIT | -132.30K | -118.20K | |||
| EBITDA | -- | -- | |||
| EPS Basic | 0.00 | -0.01 | |||
| Normalized Basic EPS | 0.00 | 0.00 | |||
| EPS Diluted | 0.00 | -0.01 | |||
| Normalized Diluted EPS | 0.00 | 0.00 | |||
| Average Basic Shares Outstanding | 38.39M | 33.91M | |||
| Average Diluted Shares Outstanding | 38.39M | 33.91M | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||